Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.
NCT ID: NCT04633915
Last Updated: 2021-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
2020-11-26
2021-07-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The research hypothesis is that dynamic of IgG antibodies against SARS-CoV-2 will differ in two groups.
To determine whether there is a statistically significant interaction between factors "group" and "time" on the titer of IgG antibodies against SARS-CoV-2, a two-way repeated measures ANOVA will be used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Protective Antibody Level After COVID-19 Vaccination Among Patients Under Hemodialysis
NCT04871945
CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19
NCT04487990
COVADIAL - Immunogenicity of COVID-19 Vaccine in Hemodialysis Patients
NCT04728828
Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients
NCT04685447
Response of Haemodialysis Patients to BNT162b2 mRNA Cov-19 Vaccine
NCT04881396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dialysis
Patients with CKD stage 5, treated with maintenance hemodialysis
No interventions assigned to this group
Healthy
Volunteers who are not dialysis-dependent
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SARS-CoV-2 infection within 10 weeks prior enrollment, confirmed by PCR or strongly suspected on computed tomography
* Providing informed consent
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saint Petersburg State University, Russia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ekaterina Parshina
Principal investigator, MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saint-Petersburg State University Hospital
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.